Biomarkers in cancer immunotherapy

Ton N Schumacher; Can Kesmir; Marit M van Buuren

doi:10.1016/j.ccell.2014.12.004

Biomarkers in cancer immunotherapy

Cancer Cell. 2015 Jan 12;27(1):12-4. doi: 10.1016/j.ccell.2014.12.004.

Authors

Ton N Schumacher¹, Can Kesmir², Marit M van Buuren³

Affiliations

¹ Division of Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands. Electronic address: t.schumacher@nki.nl.
² Department of Theoretical Biology and Bioinformatics, Utrecht University, 3584 CH Utrecht, the Netherlands.
³ Division of Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands.

PMID: 25584891
DOI: 10.1016/j.ccell.2014.12.004

Abstract

Antibodies against T cell checkpoint molecules have started to revolutionize cancer treatment. Nevertheless, less than half of all patients respond to these immunotherapies. Recent work supports the potential value of biomarkers that predict therapy outcome and inspires the development of assay systems that interrogate other aspects of the cancer-immunity cycle.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Neoplasm / therapeutic use*
Biomarkers, Tumor / genetics
Biomarkers, Tumor / immunology*
Humans
Immunotherapy / methods
Neoplasms / genetics
Neoplasms / immunology*
T-Lymphocytes / immunology

Substances

Antibodies, Neoplasm
Biomarkers, Tumor